EpidStat Institute provides scientific expertise related to health issues, pharmaceuticals, medical devices, and environmental chemicals. Our target clientele include companies and groups needing expert assistance, evaluation of complex health issues, and assistance with the conduct and interpretation of epidemiological studies.
Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Qi Y, Liu H, Jin H, Yu L, Hackett J, Villafana T, Esser MT. Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States. PLoS One. 2018 Jul 24;13(7):e0200319.
Le HQ, Tomenson JA, Warheit DB, Fryzek JP, Golden AP, Ellis ED. A Review and Meta-Analysis of Occupational Titanium Dioxide Exposure and Lung Cancer Mortality. J Occup Environ Med. 2018 Jul;60(7):e356-e367.
Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database. Adv Ther. 2018 Jun 26.
EconStat made several presentations at the recent ISPOR 2018 Congress. “Vascular Access-Specific HRQOL Impacts Among Hemodialysis Patients: The Hemodialysis Access-Related QOL (HARQ) Project Focus Group Results Results” highlighted results from qualitative research to develop a novel quality of life questionnaire for dialysis patients. Two presentations focused on economic analyses of a novel vasopressor used in the intensive care unit; the cost-effectiveness analysis showed Giapreza to be a highly cost-effective treatment for severe distributive shock in the ICU.